CSBio CSBio

X
[{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"},{"orgOrder":0,"company":"Octapharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Octapharma USA Presents Research on Congenital & Acquired Bleeding Disorders at ASH Annual Meeting","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Octapharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","amount":"$11,700.0 million","upfrontCash":"$11,700.0 million","newsHeadline":"CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferinject\u00ae Approved In Chinafor The Treatment Of Iron Deficiency In Adult Patients","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CHMP Recommends Revoking the Conditional Marketing Authorization for Adakveo\u00ae (crizanlizumab)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","amount":"$11,700.0 million","upfrontCash":"$11,700.0 million","newsHeadline":"Finalization of Vifor Pharma Acquisition","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission (EC) Adopts Decision Endorsing CHMP Recommendation to Revoke the Conditional Marketing Authorization for Adakveo\u00ae (crizanlizumab)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferinject\u00ae Granted Upgraded Recommendations in 2023 ESC Heart Failure Guidelines","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"CSL Vifor"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Ferinject (ferric carboxymaltose) is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.

            Lead Product(s): Ferric Carboxymaltose

            Therapeutic Area: Hematology Product Name: Ferinject

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Adakveo (crizanlizumab) is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions between endothelial cells, platelets, RBCs, and leukocytes and indicated for sickle cell disease.

            Lead Product(s): Crizanlizumab

            Therapeutic Area: Hematology Product Name: Adakveo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Adakveo (crizanlizumab) is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions between endothelial cells, platelets, RBCs, and leukocytes and indicated for sickle cell disease.

            Lead Product(s): Crizanlizumab-tmca

            Therapeutic Area: Hematology Product Name: Adakveo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 26, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Ferinject 50mg/ml Solution for Injection is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around your body.

            Lead Product(s): Ferric Carboxymaltose

            Therapeutic Area: Hematology Product Name: Ferinject

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).

            Lead Product(s): Ferric Carboxymaltose

            Therapeutic Area: Hematology Product Name: Ferinject

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: CSL

            Deal Size: $11,700.0 million Upfront Cash: $11,700.0 million

            Deal Type: Acquisition August 02, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).

            Lead Product(s): Ferric Carboxymaltose

            Therapeutic Area: Hematology Product Name: Ferinject

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: CSL

            Deal Size: $11,700.0 million Upfront Cash: $11,700.0 million

            Deal Type: Acquisition December 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Octapharma to present multiple clinical trial posters on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use to treat congenital and acquired bleeding disorders.

            Lead Product(s): Human Fibrinogen

            Therapeutic Area: Hematology Product Name: Fibryga

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            A pre-specified sensitivity analysis considering the impact of the COVID-19 pandemic, revealed a statistically significant difference in favor of Ferinject® on cardiovascular mortality and hospitalization for heart failure.

            Lead Product(s): Ferric Carboxymaltose

            Therapeutic Area: Hematology Product Name: Ferinject

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 24, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY